2/10/2021 11:56:50 PM
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/28/2021 11:03:12 PM
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/30/2020 7:11:06 AM
CTI BioPharma Publishes Pacritinib Data From The PAC203 Phase 2 Study In Blood Advances
11/10/2020 4:08:21 PM
CTI BioPharma Q3 Loss/Shr $0.15 Vs Loss $0.17 Last Year
10/13/2020 7:01:34 AM
CTI BioPharma Initiates Rolling Submission Of NDA For Pacritinib In Myelofibrosis Patients With Severe Thrombocytopenia
8/6/2020 4:25:15 PM
CTI BioPharma Q2 Loss/Shr $0.19, Same As Last Year
6/1/2020 7:02:42 AM
CTI BioPharma Enrolls 1st Patient In Phase 3 PRE-VENT Trial Of Pacritinib In Hospitalized Patients With Severe COVID-19